Authors
Matías Muñoz-Medel, Ignacio N Retamal, M Fernanda Fernández, Doris Durán, Juan A Godoy, Marcelo Garrido
Published in
Revista medica de Chile. Volume 154. Issue 5. Pages 693-703.
Abstract
Plasma chromogranin A (CgA) is the most accurate diagnostic biomarker for neuroendocrine tumors (NETs). However, variations in the cutoff parameters for CgA detection have resulted in non-comparable data across various countries. Notably, most Chilean patients are diagnosed with stage IV NETs, suggesting that the current consensus cut-off criteria may be insufficient for detecting early-stage cases.
To reassess chromogranin A for the diagnosis of endocrine neoplasms in a Chilean population.
This study involved measuring CgA levels in a Chilean cohort comprising a retrospective group of patients with NETs (n= 76) and healthy subjects (n= 70), totaling 146 individuals. CgA levels were assessed at diagnosis and recruitment utilizing a competitive enzyme-linked immunosorbent assay (ELISA) with polyclonal antibodies (ED kit).
Patients diagnosed with NETs exhibited increased CgA levels, with those in advanced stages demonstrating even higher levels. By employing the ROC curve and determining Youden's index, we established a plasma CgA cutoff value of 89 (ng/ml), which is lower than the threshold previously used for diagnosing Chilean patients. Elevated CgA levels were associated with a more accurate diagnosis of NETs.
Based on these findings, we propose a reassessment of the cutoff detection values to enhance the diagnosis, follow-up, and progression tracking of NETs in the Chilean population.
PMID:
42507955
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0